These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17099212)

  • 1. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis.
    Nader S; Diamanti-Kandarakis E
    Hum Reprod; 2007 Feb; 22(2):317-22. PubMed ID: 17099212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptives in polycystic ovary syndrome: risk-benefit assessment.
    Yildiz BO
    Semin Reprod Med; 2008 Jan; 26(1):111-20. PubMed ID: 18181089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome.
    Soares GM; Vieira CS; de Paula Martins W; Dos Reis RM; de Sá MF; Ferriani RA
    Int J Clin Pract; 2009 Jan; 63(1):160-9. PubMed ID: 18795969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined oral contraceptives in polycystic ovary syndrome - indications and cautions.
    Bozdag G; Yildiz BO
    Front Horm Res; 2013; 40():115-27. PubMed ID: 24002409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
    Meyer C; McGrath BP; Teede HJ
    Diabetes Care; 2007 Mar; 30(3):471-8. PubMed ID: 17327307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined oral contraceptives in the treatment of polycystic ovary syndrome.
    Vrbíková J; Cibula D
    Hum Reprod Update; 2005; 11(3):277-91. PubMed ID: 15790599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome.
    Mastorakos G; Koliopoulos C; Deligeoroglou E; Diamanti-Kandarakis E; Creatsas G
    Fertil Steril; 2006 Feb; 85(2):420-7. PubMed ID: 16595221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.
    Diamanti-Kandarakis E; Kandaraki E; Christakou C; Panidis D
    Obes Rev; 2009 Jul; 10(4):431-41. PubMed ID: 19413702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral contraceptives and insulin sensitivity.
    Cagnacci A
    Fertil Steril; 2006 Jul; 86(1):e5; author reply e6. PubMed ID: 16750203
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome.
    Pehlivanov B; Mitkov M
    Eur J Contracept Reprod Health Care; 2007 Mar; 12(1):30-5. PubMed ID: 17455042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hirsutism and acne in polycystic ovary syndrome.
    Archer JS; Chang RJ
    Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):737-54. PubMed ID: 15380144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
    Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiometabolic features of polycystic ovary syndrome.
    Hoffman LK; Ehrmann DA
    Nat Clin Pract Endocrinol Metab; 2008 Apr; 4(4):215-22. PubMed ID: 18250636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor VIII among women with polycystic ovary syndrome: An observational pilot study.
    Yousuf SD; Ganie MA; Jeelani S; Mudassar S; Shah ZA; Zargar MA; Amin S; Wani IA; Rashid F
    Indian J Med Res; 2018 Dec; 148(Suppl):S151-S155. PubMed ID: 30964093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgens in polycystic ovary syndrome: the role of exercise and diet.
    Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F
    Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives in polycystic ovary syndrome.
    Helvaci N; Yildiz BO
    Minerva Endocrinol; 2014 Sep; 39(3):175-87. PubMed ID: 25003228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The management of insulin resistance in polycystic ovary syndrome.
    Teede HJ; Hutchison SK; Zoungas S
    Trends Endocrinol Metab; 2007 Sep; 18(7):273-9. PubMed ID: 17698366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: are the molecular mechanisms distinct from type 2 diabetes?
    Corbould A
    Panminerva Med; 2008 Dec; 50(4):279-94. PubMed ID: 19078869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and metabolic characteristics of polycystic ovary syndrome without polycystic ovary: a pilot study on Chinese women.
    Shi Y; Gao X; Sun X; Zhang P; Chen Z
    Fertil Steril; 2008 Oct; 90(4):1139-43. PubMed ID: 17889857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.